MA56508A - Inhibiteur d'egfr pour le traitement du cancer - Google Patents

Inhibiteur d'egfr pour le traitement du cancer

Info

Publication number
MA56508A
MA56508A MA056508A MA56508A MA56508A MA 56508 A MA56508 A MA 56508A MA 056508 A MA056508 A MA 056508A MA 56508 A MA56508 A MA 56508A MA 56508 A MA56508 A MA 56508A
Authority
MA
Morocco
Prior art keywords
cancer
treatment
egfr inhibitor
egfr
inhibitor
Prior art date
Application number
MA056508A
Other languages
English (en)
Other versions
MA56508B1 (fr
Inventor
Cosimo Dolente
Annick Goergler
David Hewings
Georg Jaeschke
Bernd Kuhn
Yvonne Alice Nagel
Sander Ulrike Obst
Antonio Ricci
Daniel Rueher
Sandra Steiner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA56508A publication Critical patent/MA56508A/fr
Publication of MA56508B1 publication Critical patent/MA56508B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA56508A 2019-06-21 2020-06-19 Inhibiteur de l'egfr pour le traitement du cancer MA56508B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181754 2019-06-21
PCT/EP2020/067076 WO2020254562A1 (fr) 2019-06-21 2020-06-19 Inhibiteur d'egfr pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA56508A true MA56508A (fr) 2022-04-27
MA56508B1 MA56508B1 (fr) 2023-11-30

Family

ID=67139601

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56508A MA56508B1 (fr) 2019-06-21 2020-06-19 Inhibiteur de l'egfr pour le traitement du cancer

Country Status (28)

Country Link
US (4) US20220315592A1 (fr)
EP (4) EP3986895B1 (fr)
JP (4) JP7550798B2 (fr)
KR (1) KR20220024105A (fr)
CN (4) CN113966335B (fr)
AR (4) AR119206A1 (fr)
AU (1) AU2020295703A1 (fr)
BR (1) BR112021025445B1 (fr)
CA (1) CA3140485A1 (fr)
CL (1) CL2021003408A1 (fr)
CO (1) CO2021017173A2 (fr)
CR (1) CR20210624A (fr)
DK (1) DK3986897T3 (fr)
ES (1) ES2961187T3 (fr)
FI (1) FI3986897T3 (fr)
HR (1) HRP20231276T1 (fr)
HU (1) HUE063676T2 (fr)
IL (1) IL288522B1 (fr)
LT (1) LT3986897T (fr)
MA (1) MA56508B1 (fr)
MX (1) MX2021015464A (fr)
PE (1) PE20220576A1 (fr)
PL (1) PL3986897T3 (fr)
PT (1) PT3986897T (fr)
RS (1) RS64720B1 (fr)
SI (1) SI3986897T1 (fr)
TW (4) TW202115071A (fr)
WO (4) WO2020254562A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3986897T1 (sl) 2019-06-21 2023-12-29 F. Hoffmann-La Roche Ag Inhibitor EGFR za zdravljenje raka
MX2021015889A (es) 2019-06-21 2022-02-03 Hoffmann La Roche Nuevos inhibidores de egfr.
AU2023268579A1 (en) * 2022-05-13 2024-09-19 F. Hoffmann-La Roche Ag Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer
AU2023269227A1 (en) * 2022-05-13 2024-10-03 F. Hoffmann-La Roche Ag New indazole derivatives
WO2024206858A1 (fr) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions pour induire une hydrolyse de ras gtp et leurs utilisations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
CN101273033A (zh) * 2005-09-20 2008-09-24 阿斯利康(瑞典)有限公司 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物
US20110212078A1 (en) 2008-06-25 2011-09-01 Reddy Panduranga Adulla P Synthesis and use of heterocyclic antibacterial agents
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
WO2015095807A1 (fr) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Traitements du cancer au moyen de combinaisons d'inhibiteurs de l'egfr et de l'erk
CN105777756B (zh) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
JP6639497B2 (ja) * 2014-11-10 2020-02-05 ジェネンテック， インコーポレイテッド ブロモドメインインヒビターおよびその使用
MX2017014550A (es) 2015-05-14 2018-02-26 Wistar Inst Inhibidores del antigeno nuclear epstein-barr 1 (ebna1) y metodos que los utilizan.
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2018220149A1 (fr) 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Composés
WO2019046668A1 (fr) * 2017-08-31 2019-03-07 Kezar Life Sciences Thiazoles à substitution amide utilisés en tant qu'inhibiteurs de la sécrétine protéique
WO2020002487A1 (fr) 2018-06-29 2020-01-02 F. Hoffmann-La Roche Ag Composés
WO2020254544A1 (fr) 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag Nouveaux inhibiteurs d'egfr
SI3986897T1 (sl) 2019-06-21 2023-12-29 F. Hoffmann-La Roche Ag Inhibitor EGFR za zdravljenje raka
MX2021015889A (es) 2019-06-21 2022-02-03 Hoffmann La Roche Nuevos inhibidores de egfr.

Also Published As

Publication number Publication date
CL2021003408A1 (es) 2022-10-14
TW202115072A (zh) 2021-04-16
CR20210624A (es) 2022-02-14
FI3986897T3 (fi) 2023-10-20
MX2021015464A (es) 2022-01-24
AR119206A1 (es) 2021-12-01
JP2022538403A (ja) 2022-09-02
DK3986897T3 (da) 2023-10-30
LT3986897T (lt) 2023-11-10
EP3986895A1 (fr) 2022-04-27
WO2020254572A1 (fr) 2020-12-24
WO2020254562A1 (fr) 2020-12-24
JP7550798B2 (ja) 2024-09-13
EP3986896A1 (fr) 2022-04-27
HRP20231276T1 (hr) 2024-02-02
PT3986897T (pt) 2023-10-23
ES2961187T3 (es) 2024-03-08
CN113966335A (zh) 2022-01-21
JP2022538055A (ja) 2022-08-31
JP7530391B2 (ja) 2024-08-07
AR119208A1 (es) 2021-12-01
JP7550800B2 (ja) 2024-09-13
JP7550799B2 (ja) 2024-09-13
HUE063676T2 (hu) 2024-01-28
EP3986898B1 (fr) 2023-03-15
EP3986897A1 (fr) 2022-04-27
IL288522A (en) 2022-01-01
CA3140485A1 (fr) 2020-12-24
AR119210A1 (es) 2021-12-01
PE20220576A1 (es) 2022-04-20
PL3986897T3 (pl) 2024-01-22
US20220135571A1 (en) 2022-05-05
TW202115071A (zh) 2021-04-16
AU2020295703A1 (en) 2022-01-06
CN113993872A (zh) 2022-01-28
JP2022537191A (ja) 2022-08-24
CO2021017173A2 (es) 2022-01-17
JP2022537769A (ja) 2022-08-29
EP3986898A1 (fr) 2022-04-27
AR119209A1 (es) 2021-12-01
TW202115074A (zh) 2021-04-16
IL288522B1 (en) 2024-10-01
WO2020254568A1 (fr) 2020-12-24
KR20220024105A (ko) 2022-03-03
CN114008049B (zh) 2024-07-05
EP3986896B1 (fr) 2023-03-15
US20230054473A1 (en) 2023-02-23
EP3986897B1 (fr) 2023-08-30
EP3986895B1 (fr) 2023-03-15
CN113993872B (zh) 2024-09-24
CN113966335B (zh) 2024-08-02
BR112021025445B1 (pt) 2024-02-27
TW202115053A (zh) 2021-04-16
WO2020254565A1 (fr) 2020-12-24
US20220315593A1 (en) 2022-10-06
CN113993873B (zh) 2024-08-02
RS64720B1 (sr) 2023-11-30
CN114008049A (zh) 2022-02-01
MA56508B1 (fr) 2023-11-30
CN113993873A (zh) 2022-01-28
BR112021025445A2 (pt) 2022-02-01
SI3986897T1 (sl) 2023-12-29
US20220315592A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
MA55959A (fr) Dosage d'inhibiteur de kras pour le traitement de cancers
MA52780A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA52564A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
MA56050A (fr) Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA45037A (fr) Polythérapie à base d'arnm pour le traitement du cancer
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
MA51418A (fr) Inhibiteurs de glycolate oxydase pour le traitement de maladies
MA55560A (fr) Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer
MA52657A (fr) Anticorps spécifiques d'axl pour le traitement du cancer
MA51613A (fr) Polythérapie pour le traitement ou la prévention du cancer
MA50943A (fr) Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
MA55218A (fr) Eskétamine pour le traitement de la dépression
MA55490A (fr) Mutéine de lipocaline pour le traitement de l'asthme
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
MA55982A (fr) Composition pharmaceutique pour le traitement de tumeurs
MA52499A (fr) Associations pour le traitement du cancer